SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 101,400
-1,200 (-1.17%)
Last updated: Apr 29, 2026, 1:45 PM KST
SK Biopharmaceuticals Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 307,771 | 322,807 | 239,700 | 104,060 | 225,922 | Upgrade
|
| Short-Term Investments | 1,711 | 1,682 | 1,418 | 201,394 | 108,417 | Upgrade
|
| Cash & Short-Term Investments | 309,482 | 324,489 | 241,118 | 305,454 | 334,339 | Upgrade
|
| Cash Growth | -4.63% | 34.58% | -21.06% | -8.64% | -13.83% | Upgrade
|
| Accounts Receivable | 228,826 | 173,819 | 111,001 | 63,506 | 55,883 | Upgrade
|
| Other Receivables | 450.84 | 433.79 | 2,641 | 2,945 | 1,477 | Upgrade
|
| Receivables | 229,276 | 174,253 | 113,642 | 66,451 | 57,360 | Upgrade
|
| Inventory | 100,240 | 111,679 | 102,525 | 90,920 | 51,933 | Upgrade
|
| Prepaid Expenses | 28,905 | 30,125 | 25,898 | 18,734 | 20,964 | Upgrade
|
| Other Current Assets | 15,326 | 10,825 | 5,538 | 6,366 | 6,622 | Upgrade
|
| Total Current Assets | 683,229 | 651,371 | 488,722 | 487,925 | 471,219 | Upgrade
|
| Property, Plant & Equipment | 60,510 | 43,932 | 47,753 | 20,350 | 22,938 | Upgrade
|
| Long-Term Investments | 66,002 | 91,439 | 104,091 | 99,959 | 107,665 | Upgrade
|
| Goodwill | 1,650 | 1,691 | 3,392 | - | - | Upgrade
|
| Other Intangible Assets | 5,338 | 8,875 | 14,542 | 17,181 | 18,900 | Upgrade
|
| Long-Term Deferred Tax Assets | 325,775 | 206,400 | 44,723 | 29,641 | 18,919 | Upgrade
|
| Long-Term Deferred Charges | 44,227 | 21,963 | 9,090 | - | - | Upgrade
|
| Other Long-Term Assets | 11,526 | 11,059 | 10,771 | 9,107 | 3,985 | Upgrade
|
| Total Assets | 1,198,309 | 1,036,811 | 723,171 | 664,241 | 643,652 | Upgrade
|
| Accounts Payable | 9,337 | 3,403 | 2,346 | 23,106 | 16,931 | Upgrade
|
| Accrued Expenses | 94,637 | 79,653 | 71,331 | 55,035 | 64,776 | Upgrade
|
| Short-Term Debt | - | - | 50,000 | - | - | Upgrade
|
| Current Portion of Long-Term Debt | - | 150,715 | -0 | - | - | Upgrade
|
| Current Portion of Leases | 8,429 | 7,091 | 7,061 | 5,644 | 5,481 | Upgrade
|
| Current Income Taxes Payable | 2,100 | 451.82 | 88.78 | 208.36 | 1,997 | Upgrade
|
| Other Current Liabilities | 180,697 | 154,962 | 110,792 | 79,079 | 59,120 | Upgrade
|
| Total Current Liabilities | 295,200 | 396,276 | 241,619 | 163,073 | 148,306 | Upgrade
|
| Long-Term Debt | - | - | 94,484 | 143,722 | - | Upgrade
|
| Long-Term Leases | 40,491 | 26,676 | 26,505 | 6,530 | 10,256 | Upgrade
|
| Pension & Post-Retirement Benefits | - | - | - | - | 52.72 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 1,909 | - | - | Upgrade
|
| Other Long-Term Liabilities | 36,349 | 39,874 | 37,703 | 34,356 | 40,850 | Upgrade
|
| Total Liabilities | 372,039 | 462,827 | 402,219 | 347,681 | 199,465 | Upgrade
|
| Common Stock | 39,157 | 39,157 | 39,157 | 39,157 | 39,157 | Upgrade
|
| Additional Paid-In Capital | 1,084,848 | 1,084,848 | 1,084,848 | 1,084,848 | 1,084,848 | Upgrade
|
| Retained Earnings | -354,142 | -621,532 | -861,561 | -827,555 | -689,141 | Upgrade
|
| Comprehensive Income & Other | 43,173 | 43,800 | 21,243 | 20,112 | 9,325 | Upgrade
|
| Total Common Equity | 813,036 | 546,273 | 283,686 | 316,560 | 444,187 | Upgrade
|
| Minority Interest | 13,234 | 27,711 | 37,265 | - | - | Upgrade
|
| Shareholders' Equity | 826,270 | 573,984 | 320,951 | 316,560 | 444,187 | Upgrade
|
| Total Liabilities & Equity | 1,198,309 | 1,036,811 | 723,171 | 664,241 | 643,652 | Upgrade
|
| Total Debt | 48,920 | 184,482 | 178,050 | 155,896 | 15,738 | Upgrade
|
| Net Cash (Debt) | 260,562 | 140,007 | 63,068 | 149,558 | 318,602 | Upgrade
|
| Net Cash Growth | 86.11% | 121.99% | -57.83% | -53.06% | -13.78% | Upgrade
|
| Net Cash Per Share | 3327.18 | 1787.78 | 805.33 | 1909.74 | 4068.30 | Upgrade
|
| Filing Date Shares Outstanding | 78.31 | 78.31 | 78.31 | 78.31 | 78.31 | Upgrade
|
| Total Common Shares Outstanding | 78.31 | 78.31 | 78.31 | 78.31 | 78.31 | Upgrade
|
| Working Capital | 388,029 | 255,095 | 247,104 | 324,852 | 322,914 | Upgrade
|
| Book Value Per Share | 10381.84 | 6975.49 | 3622.46 | 4042.23 | 5671.93 | Upgrade
|
| Tangible Book Value | 806,048 | 535,708 | 265,752 | 299,380 | 425,288 | Upgrade
|
| Tangible Book Value Per Share | 10292.61 | 6840.58 | 3393.45 | 3822.85 | 5430.60 | Upgrade
|
| Machinery | 32,819 | 32,717 | 30,611 | 21,078 | 19,165 | Upgrade
|
| Construction In Progress | 4,591 | 201.95 | 236.84 | 1,643 | 1,276 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.